• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Ex-Spectranetics CEO’s conviction stands

Ex-Spectranetics CEO’s conviction stands

March 5, 2014 By Brad Perriello

Ex-Spectranetics CEO's conviction stands

Former Spectranetics (NSDQ:SPNC) CEO John Schulte’s 2012 conviction on a single count of lying to federal investigators survived his appeal to an appeals court, meaning his sentence of a year’s probation will stand.

Schulte was convicted in March 2012 for his role in the allegedly illegal importation of medical devices for a clinical trial and sentenced later that year.

In January, the U.S. Appeals Court for the 10th Circuit denied Schulte’s appeal, shooting down his argument that his statements were not aimed at misleading an FDA investigation into the case, according to court documents. A jury acquitted Schulte of 11 other charges including conspiracy to defraud the federal government.

Spectranetics agreed to pay $5 million and admitted responsibility late in 2009 to settle its portion of the case, after federal agents raided its Colorado Springs headquarters in 2008. Schulte resigned a few weeks after the raid and was indicted in 2010, along with 3 other defendants – former vice president of business development Obinna "Larry" Adighije, former business development manager Trung Pham and consultant Hernan Ricuarte.

Pham was acquitted of the 5 charges against him, including conspiring to defraud the federal government and smuggling unapproved medical devices into the country; prosecutors later dropped all 5 charges against Adighije. Ricuarte pleaded guilty in August 2012 to a single count of concealing a felony.

Schulte argued that in his conviction and subsequent sentencing "the government failed to prove both his intent to supply false information and the materiality of the statements to the government’s investigation," according to the documents. The 10th Circuit disagreed, affirming the conviction in a Jan. 21 ruling. The appeals court denied Schulte’s bid for a re-hearing Feb. 18, according to the documents.

"Given Schulte’s position in the company and his ability to explain the purpose and use of the devices prior to FDA approval, the jury was provided sufficient evidence to find, beyond a reasonable doubt, Schulte’s statements could have influenced the agency," according to the documents. "The FDA, charged with protecting citizens’ health, was trying to ascertain the number and type of unapproved devices placed into human patients. Schulte’s statements misdirected the focus of the investigation from a company policy soliciting clinical trials to the possible, but unknown activities of individual employees."

Filed Under: Food & Drug Administration (FDA), Legal News, News Well Tagged With: Spectranetics Corp.

More recent news

  • Neuralink files to raise $649M in new equity offering
  • BofA: Surgical robot remanufacturing not a major setback for Intuitive
  • InspireMD wins CE Mark approval for CGuard Prime
  • Philips reports first cases for VeriSight Pro 3D ICE catheter in Europe
  • Ceryx Medical raises $15M to support bioelectronic pacemaker

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy